Search research articles
Contact Us
Filters
Showing results (1-10 of 126) with videos related to
Page
of 13
Sort By:
Therapie
|
September 23, 2006
[Pharmacokinetics-pharmacodynamics of antifungal drugs. Consequences for therapeutic drug monitoring]
Vincent Jullien, Olivier Lortholary
Clinical Pharmacokinetics
|
March 14, 2008
Facilitation of drug evaluation in children by population methods and modelling
Michel Tod, Vincent Jullien, Gérard Pons
Pharmaceutical Research
|
June 2, 2021
Conditional Non-parametric Bootstrap for Non-linear Mixed Effect Models
Emmanuelle Comets, Christelle Rodrigues, Vincent Jullien, et al.
Pharmaceutical Research
|
February 7, 2008
A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Application to amoxicillin-clavulanate
Michel Tod, Franck Lagneau, Vincent Jullien, et al.
Clinical Pharmacokinetics
|
September 12, 2008
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients
Benoit Blanchet, Vincent Jullien, Christophe Vinsonneau, et al.
Hypertension (Dallas, Tex. : 1979)
|
June 28, 2017
Detecting Nonadherence to Antihypertensive Treatment: Any Time, Anywhere?
Idir Hamdidouche, Vincent Jullien, Stéphane Laurent, et al.
Current HIV Research
|
January 4, 2012
HIV drug resistance on HAART despite an undetectable viral load
Pierre Loulergue, Constance Delaugerre, Vincent Jullien, et al.
European Journal of Pharmacology
|
May 14, 2003
S-15176 inhibits mitochondrial permeability transition via a mechanism independent of its antioxidant properties
Aziz Elimadi, Vincent Jullien, Jean Paul Tillement, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
January 30, 2003
Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection
Vincent Jullien, Jean-Marc Tréluyer, Gérard Pons, et al.
The Journal of Antimicrobial Chemotherapy
|
March 25, 2016
Rifabutin: where do we stand in 2016?
Yoann Crabol, Emilie Catherinot, Nicolas Veziris, et al.
Page
of 13
Search research articles
Search
Showing results (1-10 of 126) with videos related to
Sort By:
Page
of 13
Therapie
|
September 23, 2006
[Pharmacokinetics-pharmacodynamics of antifungal drugs. Consequences for therapeutic drug monitoring]
Vincent Jullien, Olivier Lortholary
Clinical Pharmacokinetics
|
March 14, 2008
Facilitation of drug evaluation in children by population methods and modelling
Michel Tod, Vincent Jullien, Gérard Pons
Pharmaceutical Research
|
June 2, 2021
Conditional Non-parametric Bootstrap for Non-linear Mixed Effect Models
Emmanuelle Comets, Christelle Rodrigues, Vincent Jullien, et al.
Pharmaceutical Research
|
February 7, 2008
A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Application to amoxicillin-clavulanate
Michel Tod, Franck Lagneau, Vincent Jullien, et al.
Clinical Pharmacokinetics
|
September 12, 2008
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients
Benoit Blanchet, Vincent Jullien, Christophe Vinsonneau, et al.
Hypertension (Dallas, Tex. : 1979)
|
June 28, 2017
Detecting Nonadherence to Antihypertensive Treatment: Any Time, Anywhere?
Idir Hamdidouche, Vincent Jullien, Stéphane Laurent, et al.
Current HIV Research
|
January 4, 2012
HIV drug resistance on HAART despite an undetectable viral load
Pierre Loulergue, Constance Delaugerre, Vincent Jullien, et al.
European Journal of Pharmacology
|
May 14, 2003
S-15176 inhibits mitochondrial permeability transition via a mechanism independent of its antioxidant properties
Aziz Elimadi, Vincent Jullien, Jean Paul Tillement, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
January 30, 2003
Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection
Vincent Jullien, Jean-Marc Tréluyer, Gérard Pons, et al.
The Journal of Antimicrobial Chemotherapy
|
March 25, 2016
Rifabutin: where do we stand in 2016?
Yoann Crabol, Emilie Catherinot, Nicolas Veziris, et al.
Page
of 13